Log In Sign up
The largest database of trusted experimental protocols

Ab77668

Manufactured by Abcam
Visit Supplier

Ab77668 is a laboratory product offered by Abcam. It serves as a core piece of equipment for scientific research and experimentation. The detailed specifications and intended use of this product are not available for an unbiased and factual description.

Automatically generated - may contain errors

Lab products found in correlation

Ab2426, by Abcam (2 mentions) Mk 8776, by Selleck Chemicals (2 mentions) Thz531 a8736, by Apexbio (2 mentions) Tak 931 ct tak931, by Chemietek (2 mentions) Egfr antibody 610017, by BD (2 mentions) Xl413, by Selleck Chemicals (2 mentions) Ab62322, by Abcam (2 mentions)

2 protocols using ab77668

1

Inhibitors Targeting Cellular Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
XL413 (S7547), BMS265246 (S2014), ON-01910 (S1362), PD0166285 (S8148), LDC000067 (S7461), PF-03814735 (S2725), D 4476 (S7642), VE-821 (S8007), AZD8055 (S1555), AZD2014 (S2783), AZD6738 (S7693) and MK-8776 (2735) were purchased from Selleck Chemicals. THZ531 (A8736) was purchased from ApexBio. XL413 (205768), BLU9931 (206192) and LY3177833 (206762) were purchased from MedKoo. TAK-931 (CT-TAK931) was purchased from Chemietek. XL413 (A13677) was also purchased from AdooQ BIOSCIENCE. The SHP2 inhibitor used in this study is covered by a patent application (WO 2015/107495A1; compound #57) and was synthesized as described previously23 (link).
Antibodies against HSP90 (sc-7947, sc-13119), p53 (sc-126), p21 (sc-6246), and SHP2 (sc-280) were purchased from Santa Cruz Biotechnology. Antibodies against CDC7 (ab77668), p-MCM2 (ab109133, ab133243), MCM2 (ab4461), p-SHP2 (ab62322), PCNA (ab2426), and Cleaved caspase-3 (ab2303) were purchased from Abcam. Antibodies against γH2AX (#9718), p-S6RP (#4856, #5364), S6RP (#2317), p-4EBP1 (#9456, #2855, #9455), 4EBP1 (#9644), p-IGF-1R/INSR (#3024), IGF-1R (#9750), p-PDGFRβ (#3161), PDGFRβ (#4564), p-AKT (#4060), and AKT (#2920) were purchased from Cell Signalling. EGFR antibody (610017) was purchased from BD Biosciences. H3K9Me3 antibody (49-1008) and p-EGFR (44-788) were from Thermo Fisher Scientific.
Wang C., Vegna S., Jin H., Benedict B., Lieftink C., Ramirez C., Leite de Oliveira R., Morris B., Gadiot J., Wang W., du Chatinier A., Wang L., Gao D., Evers B., Jin G., Xue Z., Schepers A., Jochems F., Mulero Sanchez A., Mainardi S., te Riele H., Beijersbergen R.L., Qin W., Akkari L, & Bernards R. (2019). Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature, 574(7777), 268-272.
+ Open protocol
+ Expand
2

Inhibitors Targeting Cellular Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
XL413 (S7547), BMS265246 (S2014), ON-01910 (S1362), PD0166285 (S8148), LDC000067 (S7461), PF-03814735 (S2725), D 4476 (S7642), VE-821 (S8007), AZD8055 (S1555), AZD2014 (S2783), AZD6738 (S7693) and MK-8776 (2735) were purchased from Selleck Chemicals. THZ531 (A8736) was purchased from ApexBio. XL413 (205768), BLU9931 (206192) and LY3177833 (206762) were purchased from MedKoo. TAK-931 (CT-TAK931) was purchased from Chemietek. XL413 (A13677) was also purchased from AdooQ BIOSCIENCE. The SHP2 inhibitor used in this study is covered by a patent application (WO 2015/107495A1; compound #57) and was synthesized as described previously23 (link).
Antibodies against HSP90 (sc-7947, sc-13119), p53 (sc-126), p21 (sc-6246), and SHP2 (sc-280) were purchased from Santa Cruz Biotechnology. Antibodies against CDC7 (ab77668), p-MCM2 (ab109133, ab133243), MCM2 (ab4461), p-SHP2 (ab62322), PCNA (ab2426), and Cleaved caspase-3 (ab2303) were purchased from Abcam. Antibodies against γH2AX (#9718), p-S6RP (#4856, #5364), S6RP (#2317), p-4EBP1 (#9456, #2855, #9455), 4EBP1 (#9644), p-IGF-1R/INSR (#3024), IGF-1R (#9750), p-PDGFRβ (#3161), PDGFRβ (#4564), p-AKT (#4060), and AKT (#2920) were purchased from Cell Signalling. EGFR antibody (610017) was purchased from BD Biosciences. H3K9Me3 antibody (49-1008) and p-EGFR (44-788) were from Thermo Fisher Scientific.
Wang C., Vegna S., Jin H., Benedict B., Lieftink C., Ramirez C., Leite de Oliveira R., Morris B., Gadiot J., Wang W., du Chatinier A., Wang L., Gao D., Evers B., Jin G., Xue Z., Schepers A., Jochems F., Mulero Sanchez A., Mainardi S., te Riele H., Beijersbergen R.L., Qin W., Akkari L, & Bernards R. (2019). Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature, 574(7777), 268-272.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!